Journals / Turkish Journal of Gastroenterology / 2020 / Cilt: 31 - Sayı: 2

Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib

Pages
184–186
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

NUNES, G., FONSECA, C., PATITA, M., ALEXIO, M. J., RAMALHO, M., FONSECA, J. (2020). Diffuse advanced hepatocellular carcinoma after HCV eradication in an HIV-infected patient: A unique complete response to sorafenib. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 2, 184–186. https://ajindex.com/articles/408711

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. European Association for the Study of the Liver. Electronic ad dress: [email protected]; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of he patocellular carcinoma. J Hepatol 2018; 69: 182-236
  2. De Nardo P, Viscione M, Corpolongo A, et al. Treatment of Recur rent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-In fected patient in HAART: A Case Report. Infect Agent Cancer 2012; 7: 15
  3. Chelis L, Ntinos N, Souftas V, et al. Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART? A case report. Med Oncol 2011; 28: 165-8
  4. Berreta M, Di Benedetto, Dal Maso L, et al. Sorafenib for the treat ment of unresectable hepatocellular carcinoma in HIV-positive pa tients. Anticancer Drugs 2013; 24: 212-8
  5. Rimola J, Díaz-González Á, Darnell A, et al. Complete response un der sorafenib in patients with hepatocellular carcinoma: Relation ship with dermatologic adverse events. Hepatology 2018; 67: 912- 22.